China guideline for liver cancer screening (2022, Beijing)
10.3760/cma.j.cn112152-20220720-00502
- VernacularTitle:中国人群肝癌筛查指南(2022，北京)
- Author:
Jie HE
1
;
Wanqing CHEN
;
Hongbing SHEN
;
Ni LI
;
Chunfeng QU
;
Jufang SHI
;
Feng SUN
;
Jing JIANG
;
Guangwen CAO
;
Guihua ZHUANG
;
Ji PENG
Author Information
1. 国家癌症中心 国家肿瘤临床医学研究中心 中国医学科学院北京协和医学院肿瘤医院，北京 100021
- Keywords:
Liver neoplasms;
Screening;
Surveillance;
Guideline;
China
- From:
Chinese Journal of Oncology
2022;44(8):779-814
- CountryChina
- Language:Chinese
-
Abstract:
In China, the survival rate of liver cancer remains low while the mortality rate is high. Effectively reducing the burden of liver cancer is still a major challenge in the field of public health and chronic disease prevention in the Chinese population. Optimizing screening strategies for liver cancer remains a profound approach to secondary prevention worthy of continuous exploration. To address this pressing issue, the Bureau of Disease Control and Prevention of the National Health Commission commissioned this guideline. The National Cancer Center of China initiated the guideline development and convened a multidisciplinary expert panel and working groups. Following the World Health Organization Handbook for Guideline Development, this guideline integrated the most up-to-date evidence of liver cancer screening, China′s national conditions, and existing practical experience in liver cancer screening. Evidence-based recommendations on the target population, screening technologies, surveillance strategies, and other key points across the process of liver cancer screening and surveillance management were provided. This guideline would help standardize the practice of liver cancer screening in China.
